Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Kairos Pharma, Ltd. ( (KAPA) ) has issued an update.
Kairos Pharma Ltd. announced the presentation of new data on its investigational small molecule GITR ligand agonist, KROS101, at the American Society of Clinical Oncology 2025 Annual Meeting. The study highlighted KROS101’s dual mechanisms of action in enhancing T cell function and reducing immune suppression, showing superiority over the previously trialed anti-GITR antibody TRX518. These findings support further study of KROS101 as a promising cancer immunotherapy, potentially optimizing cancer treatment and addressing significant unmet medical needs.
The most recent analyst rating on (KAPA) stock is a Buy with a $12.00 price target. To see the full list of analyst forecasts on Kairos Pharma, Ltd. stock, see the KAPA Stock Forecast page.
More about Kairos Pharma, Ltd.
Kairos Pharma Ltd., based in Los Angeles, California, is a clinical stage biopharmaceutical company focused on oncology therapeutics. The company utilizes structural biology to address drug resistance and immune suppression in cancer. Its lead candidate, ENV105, targets CD105 to reverse drug resistance and is currently in Phase 2 clinical trials for castrate-resistant prostate cancer and Phase 1 trials for lung cancer.
Average Trading Volume: 170,927
Technical Sentiment Signal: Strong Sell
For a thorough assessment of KAPA stock, go to TipRanks’ Stock Analysis page.